Prolonged Survival of Patients Receiving Trastuzumab beyond Disease Progression for HER2 Overexpressing Metastatic Breast Cancer (MBC)

作者
Hans‐Joachim Stemmler,Steffen Kahlert,Wolfgang Siekiera,Michael Untch,Bernhard Heinrich,Volker Heinemann
出处
期刊:Oncology Research and Treatment [Karger Publishers]
卷期号:28 (11): 582-586 被引量:60
标识
DOI:10.1159/000088296
摘要

BACKGROUND: The aim of this retrospective analysis was to evaluate the impact of trastuzumab-based regimens on the survival of patients with HER2-overexpressing metastatic breast cancer (MBC). The study specifically focussed on the influence of the continuation of trastuzumab-based treatment despite tumor progression on survival. PATIENTS AND METHODS: Patients with HER2 overexpressing MBC were included in this retrospective analysis. HER2 overexpression was determined by the immunohistochemical staining score (DAKO Hercep Test). Trastuzumab was applied at a loading dose of 4 mg/kg and a maintenance dose of 2 mg/kg. RESULTS: Among 136 HER2 overexpressing patients (DAKO score 3+), 66 patients received first-line trastuzumab, 47 patients received trastuzumab as second-line therapy and 23 patients received trastuzumab beyond disease progression. There was no significant difference regarding the duration of trastuzumab-based treatment (first-line: 29.5 weeks vs. second-line: 25 weeks). Moreover, there was no difference in the response rate (first-line: 37.9% vs. second-line: 35.7%) or the median survival (p = 0.47 log rank). Patients who received = 2 trastuzumab-based regimens for MBC survived significantly longer compared to those who had received only 1 regimen (= 2 regimens: 62.4 months vs. 1 regimen: 38.5 months; p = 0.01 log rank). CONCLUSIONS: Trastuzumab is highly effective in the treatment of HER2 overexpressing MBC. Compared to historical controls, overall survival appears to be markedly prolonged, particularly in patients who received sequential trastuzumab-based treatment beyond disease progression.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
嘻嘻哈哈的应助被ri_290采纳,获得10
刚刚
2秒前
852的应助被虚心的向秋采纳,获得10
2秒前
瘦瘦草丛完成签到,获得积分10
2秒前
long发布了新的文献求助10
3秒前
嘻嘻哈哈的应助被整齐从蓉采纳,获得10
3秒前
深情安青的应助被Dylan采纳,获得10
4秒前
胡帅完成签到 ,获得积分10
4秒前
123发布了新的文献求助10
4秒前
郝子凯发布了新的文献求助10
4秒前
molihuakai的应助被夹个紧采纳,获得10
5秒前
汉堡包的应助被饺子采纳,获得10
5秒前
嗨Honey发布了新的文献求助10
5秒前
5秒前
5秒前
6秒前
金婷完成签到,获得积分10
7秒前
Voyager发布了新的文献求助10
7秒前
7秒前
在水一方的应助被晨晨采纳,获得20
7秒前
zuo完成签到,获得积分10
7秒前
CipherSage的应助被黄姗姗采纳,获得10
8秒前
9秒前
9秒前
zjujirenjie发布了新的文献求助10
11秒前
11秒前
今者当歌完成签到,获得积分10
11秒前
薛亮完成签到,获得积分20
12秒前
12秒前
任性星星完成签到 ,获得积分10
12秒前
爆米花的应助被欣慰的千易采纳,获得10
12秒前
第一作者发布了新的文献求助10
12秒前
15秒前
15秒前
16秒前
17秒前
momo完成签到,获得积分10
17秒前
CXY关注了科研通微信公众号
18秒前
jeak完成签到,获得积分10
18秒前
桉_发布了新的文献求助10
19秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8187707
求助须知:如何正确求助?哪些是违规求助? 9575782
关于积分的说明 21843037
捐赠科研通 7785576
什么是DOI,文献DOI怎么找? 3435097
关于科研通互助平台的介绍 2559495
邀请新用户注册赠送积分活动 2481986